fda approved oral semaglutide Wegovy for obesity management by on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Wegovy® Pill | GoodGirlRx

37(7): 6879 Bohan TP, Helton E, McDonald I, et al

Synthetic peptide medications can help promote significant weight loss, but they work best when paired with a balanced eating plan and regular exercise

Food and Drug Administration (FDA) has approved an expanded indication for the TRUFILL nBCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (SDH) as an adjunct to surgery.* #TRUFILLMMA #JNJMEDTECH US_NEU_HEMO_410469 *Intended for US HCP Audience Important information: Prior to use, refer to the instructions for use for indications, contraindications, side effects, warnings and precautions

If they persist or worsen, consult your healthcare provider